<DOC>
	<DOC>NCT01975350</DOC>
	<brief_summary>There might be additional benefit on clinical outcomes from adjunctive colistimethate sodium inhalation as therapy for multidrug resistant Gram-negative ventilator-associated pneumonia.</brief_summary>
	<brief_title>Efficacy Study of Colistimethate Sodium Inhalation in Patients With Ventilator-associated Pneumonia</brief_title>
	<detailed_description>Besides, early antibiotics intervention might be benefit for patients with ventilator-associated tracheobronchitis or lower airway colonization with multidrug resistant Gram-negative bacteria.</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>1. age ≥ 20 years old 2. medical ICU patients with invasive ventilator use ≥ 48 hours 3. multidrug resistant Gramnegative bacteria obtained from lower respiratory tract 1. pregnancy 2. concurrent use of other antimicrobial agents active for isolated multidrug resistant Gramnegative bacteria (as defined as resistant to carbapenem, fluoroquinolone, and antipseudomonas betalactams), such as tigecycline, aminoglycosides, and sulbactam 3. patients who refuse to receive any inhaled therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Colistimethate sodium inhalation</keyword>
</DOC>